New Drugs, Therapeutic Strategies, and Future Direction for the Treatment of Pulmonary Arterial Hypertension

(E-pub Ahead of Print)

Author(s): Valentina Mercurio*, Anna Bianco, Giacomo Campi, Alessandra Cuomo, Nermin Diab, Angela Mancini, Paolo Parrella, Mario Petretta, Paul Hassoun, Domenico Bonaduce.

Journal Name: Current Medicinal Chemistry

Submit Manuscript
Submit Proposal


Despite recent advances in pulmonary arterial hypertension (PAH) treatment, this condition is still characterized by an extremely poor prognosis. In this review, we discuss the use of newly-approved drugs for PAH treatment with already known mechanisms of action (macitentan), innovative targets (riociguat and selexipag), and novel therapeutic approaches with initial up-front combination therapy. Secondly, we describe new potential signaling pathways and investigational drugs with promising role in the treatment of PAH.

Keywords: Pulmonary Hypertension, endothelin receptor, soluble guanylate cyclase, prostanoids, initial combination therapy, gene therapy, serotonin, inflammation, immunity, metabolism, pulmonary arterial denervation.

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/0929867325666180201095743
Price: $95

Article Metrics

PDF: 39